# US 2010/0303718 A1 · Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303718 A1
- Document ID: US20100303718A1
- Status: Published application
- Kind: A1
- Application number: 12/854,631
- Filed: 2010-08-11
- Published: 2010-12-02
- Earliest claimed: 2003-10-08
- Assignees: Lyotropic Therapeutics, Inc.
- Inventors: David Anderson
- Web page: https://patentgrep.com/patent/US20100303718A1

## CPC

- C09K 19/02: characterised by optical, electrical or physical properties of the components, in general
- A61K 9/1274: Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A61P 23/00: Anaesthetics
- A61P 23/02: Local anaesthetics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C09K: MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.

## Claims

### Claim at position 1

1-200. (canceled)

### Claim 201

A composition pharmaceutically acceptable for injection in a mammal, comprising:
(i) a plurality of uncoated, ionically charged particles comprising reversed cubic phase or reversed hexagonal phase material which includes at least one charged, bilayer associated ingredient wherein a total of all charged, bilayer associated ingredients in the reversed cubic phase or reversed hexagonal phase material is between 0.02:1 and 0.08:1, and
(ii) a liquid comprising a polar solvent,
said uncoated, ionically charged particles being stabilized in dispersion in said liquid, and
said uncoated, ionically charged particles have a size of from 40 nm to 10 microns.

### Claim 202 (depends on 201)

The composition of claim 201 further comprising at least one active incorporated in said uncoated, ionically charged particles.

### Claim 202 (depends on 202)

The composition of claim 202 wherein said reversed cubic phase or reversed hexagonal phase material comprises phosphatidylcholine.

### Claim 203 (depends on 202)

The composition of claim 202 wherein said at least one active is solubilized in said reversed cubic phase or reversed hexagonal phase material.

### Claim 204 (depends on 202)

The composition of claim 202 wherein said active is dissolved in said reversed cubic phase or reversed hexagonal phase material.

### Claim 205 (depends on 202)

The composition of claim 202 wherein said active is a liquid that is embedded, dissolved, dispersed or otherwise incorporated within said reversed cubic phase or reversed hexagonal phase material.

### Claim 206 (depends on 202)

The composition of claim 202 wherein said active is solubilized in a liquid that is embedded, dissolved, dispersed or otherwise incorporated within said reversed cubic phase or reversed hexagonal phase material.

### Claim 207 (depends on 202)

The composition of claim 202 wherein said active is dispersed in said reversed cubic phase or reversed hexagonal phase material in the form of crystals or an amorphous solid.

### Claim 208 (depends on 202)

The composition of claim 202 wherein said active is a cancer therapeutic agent.

### Claim 209 (depends on 208)

The composition of claim 208 wherein said active cancer therapeutic agent is selected from the group consisting of camptothecins, taxanes, rubicins and amphotericin B.

### Claim 210 (depends on 202)

The composition of claim 202 wherein said active is a polypeptide.

### Claim 211 (depends on 202)

The composition of claim 202 wherein said active is a protein.

### Claim 212 (depends on 211)

The composition of claim 211 wherein said protein is selected from the group consisting of insulin and erythropoietin.

### Claim 213 (depends on 202)

The composition of claim 202 wherein said active is an amino acid.

### Claim 214 (depends on 202)

The composition of claim 202 wherein said active is a polysaccharide.

### Claim 215 (depends on 202)

The composition of claim 202 wherein said active is a lectin.

### Claim 216 (depends on 202)

The composition of claim 202 wherein said active is an antibody.

### Claim 217 (depends on 202)

The composition of claim 202 wherein said active is a receptor.

### Claim 218 (depends on 202)

The composition of claim 202 wherein said active is a nucleic acid.

### Claim 219 (depends on 202)

The composition of claim 202 wherein said active is a vitamin.

### Claim 220 (depends on 202)

The composition of claim 202 wherein said active is a general anesthetic agent.

### Claim 221 (depends on 220)

The composition of claim 220 wherein said general anesthetic agent is selected from the group consisting of propofol, alphaxalone, alfadolone, eltanolone, propanidid, ketamine, pregnanolone, and etomidate.

### Claim 222 (depends on 220)

The composition of claim 220 wherein said general anesthetic agent is propofol.

### Claim 223 (depends on 220)

The composition of claim 220 wherein said general anesthetic agent is etomidate.

### Claim 224 (depends on 220)

The composition of claim 220 wherein said active is a local anesthetic agent.

### Claim 225 (depends on 224)

The composition of claim 224 wherein said local anesthetic agent is selected from the group consisting of bupivacaine, lidocaine, procaine, tetracaine, mepivacaine, etidocaine, oxybuprocaine, cocaine, benzocaine, pramixine, prilocaine, proparacaine, ropivicaines, chloroprocaine, and dibucaine.

### Claim 226 (depends on 224)

The composition of claim 224 wherein said local anesthetic agent is bupivacaine.

### Claim 227 (depends on 202)

The composition of claim 202 wherein said active is an anesthetic reversal agent.

### Claim 228 (depends on 202)

The composition of claim 202 wherein said active is an enzyme.

### Claim 229 (depends on 202)

The composition of claim 202 wherein said active is a radioactive agent.

### Claim 230 (depends on 202)

The composition of claim 202 wherein said active is a toxin.

### Claim 231 (depends on 202)

The composition of claim 202 wherein said active is a steroid.

### Claim 232 (depends on 202)

The composition of claim 202 wherein said active is a hormone.

### Claim 233 (depends on 202)

The composition of claim 202 wherein said active is an immunogen.

### Claim 234 (depends on 202)

The composition of claim 202 wherein said active is a vaccine adjuvant.

### Claim 235 (depends on 202)

The composition of claim 202 wherein said active is a biomacromolecule.

### Claim 236 (depends on 202)

The composition of claim 202 wherein said active is an agonist.

### Claim 237 (depends on 202)

The composition of claim 202 wherein said active is an antagonist.

### Claim 238 (depends on 202)

The composition of claim 202 wherein said active is a bioactive agent.

### Claim 239 (depends on 202)

The composition of claim 202 wherein said active is a medicament.

### Claim 240 (depends on 202)

The composition of claim 202 wherein said active is a nonsteroidal anti-inflammatory agent.

### Claim 241 (depends on 202)

The composition of claim 202 wherein said nonsteroidal anti-inflammatory agent is selected from the group consisting of salicylates, para-aminophenol derivatives, acetaminophen, fenomates, proprionic acid derivatives, naproxen and ibuprofen.

### Claim 241 (depends on 202)

The composition of claim 202 wherein said active is selected from the group consisting of coenzyme Q10, benzodiazepines, diazepam, and barbiturates.

### Claim 242 (depends on 202)

The composition of claim 202 wherein said active is an amide or an ester.

### Claim 243 (depends on 202)

The composition of claim 202 wherein said active is a photodynamic therapy agent

### Claim 244 (depends on 202)

The composition of claim 202 wherein said active is a radiopaque or optically dense material used for imaging.

### Claim 246 (depends on 202)

The composition of claim 202 wherein said reversed cubic phase or reversed hexagonal phase material comprises a pluronic with less than 30% PEO groups by weight.

### Claim 247 (depends on 202)

The composition of claim 202 further comprising an essential oil.

### Claim 248 (depends on 201)

The composition of claim 201 wherein said particle zeta potential has a magnitude greater than or equal to 25 millivolts.

### Claim 249 (depends on 201)

The composition of claim 201 wherein said charged bilayer associated ingredient is selected from the group consisting of eugenol, isoeugenol, quinolines, hydroxyquinolines, benzoquinolines, tricyclics, pigments, chlorophyll, natural oil extracts, biosurfactants, dyes, gramicidin, casein, albumin, glycoproteins, lipid-anchored proteins, receptor proteins, proteinase A, amyloglucosidase, enkephalinase, dipeptidyl peptidase IV, gamma-glutamyl transferase, galactosidase, neuraminidase, alpha-mannosidase, cholinesterase, arylamidase, surfactin, ferrochelatase, spiralin, penicillin-binding proteins, microsomal glycotransferases, kinases, bacterial outer membrane proteins, and histocompatibility antigens.

### Claim 250 (depends on 201)

The composition of claim 201 wherein said charged bilayer associated ingredient is a salt of a deoxycholic acid or a related cholate.

### Claim 251 (depends on 250)

The composition of claim 250 wherein said salt is glycocholate.

### Claim 252 (depends on 201)

The composition of claim 201 wherein said charged bilayer associated ingredient is a charged surfactant.

### Claim 253 (depends on 201)

The composition of claim 201 wherein said charged bilayer associated ingredient is an active.

### Claim 254 (depends on 202)

The composition of claim 202 wherein said reversed cubic phase or reversed hexagonal phase material comprises a high partition coefficient diluent.

### Claim 255 (depends on 254)

The composition of claim 254 wherein said high partition coefficient diluent is selected from the group consisting of tocopherols, benzyl benzoate, estragole, eugenol, isoeugenol, linalool, strawberry aldehyde, terpineol, and the following essential oils: balsam of Peru, basil, bay, bois de rose (rosewood), carrot seed, clovebud, eucalyptus, ginger, grapefruit, hyssop, lemon, mugwort, myrrh gum, bitter orange, oregano, palmarosa, patchouly, peppermint, petitgrain, rosemary, santalwood oil, spearmint, thuja (cedar leaf), thyme, vanilla, and ylang ylang (cananga).

### Claim 256 (depends on 201)

The composition of claim 201 wherein said particle zeta potential has a magnitude greater than 30 millivolts.

### Claim 257 (depends on 201)

The composition of claim 201 wherein said particle zeta potential has a magnitude greater than 45 millivolts.

### Claim 258 (depends on 201)

The composition of claim 201 wherein said particle zeta potential has a magnitude greater than 55 millivolts.

### Claim 259 (depends on 201)

The composition of claim 201 wherein said reversed cubic phase or reversed hexagonal phase material includes phosphatidylcholine and further comprising tocopherol.

### Claim 260 (depends on 202)

The composition of claim 202 further comprising a targeting moiety associated with said uncoated, charged particles.
